EAM Investors’s Karyopharm Therapeutics KPTI Stock Holding History

EAM Investors’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-11,923	Closed	-$3.44M	–	286
2020 Q1	$3.44M	Buy	11,923 +145	+1%	+$40K	1.07%	7
2019 Q4	$3.39M	Buy	+11,778	New	+$2.56M	0.75%	25
2017 Q2	–	Sell	-17,974	Closed	-$3.46M	–	327
2017 Q1	$3.46M	Buy	+17,974	New	+$2.89M	0.55%	47
2014 Q2	–	Sell	-4,253	Closed	-$1.97M	–	341
2014 Q1	$1.97M	Buy	+4,253	New	+$2.16M	0.36%	91

Other funds holding KPTI

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

EAM Investors's KPTI Position: Q2 2020 in Review

EAM Investors sold out of Karyopharm Therapeutics (KPTI) in Q2 2020, closing a stake of 11,923 shares — an estimated $3.44M sold.

EAM Investors first reported a position in KPTI in Q1 2014 and held it in 4 quarters. The position peaked at $3.46M in Q1 2017. 155 funds tracked by Wall St. Rank hold KPTI as of Q2 2020.

EAM Investors reported no remaining Karyopharm Therapeutics position as of Q2 2020 after selling out during the quarter.
EAM Investors sold 11,923 Karyopharm Therapeutics shares in Q2 2020, an estimated $3.44M.
EAM Investors first reported a position in Karyopharm Therapeutics in Q1 2014 and held it in 4 quarters.
EAM Investors's Karyopharm Therapeutics position peaked at $3.46M in Q1 2017.
155 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2020.

Based on EAM Investors's 13F filing for Q2 2020, filed 13 Aug 2020.